Test Price
2,800 AED✅ Home Collection Available
SERPINB6 Gene Deafness, Autosomal Recessive Type 91 Genetic Test in UAE
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% diagnostic sensitivity with ISO‑accredited processing and dual‑read variant validation using next‑generation sequencing.
Premium Logistics: VIP mobile phlebotomy and temperature‑controlled cold‑chain home collection available daily from 8 AM to 11 PM for standard blood specimens.
Clinical Guidance: Complimentary telephonic post‑test clinical guidance in result interpretation by a DHA‑licensed consultant medical geneticist.
Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This highly sensitive next‑generation sequencing (NGS) assay screens the entire coding region of the SERPINB6 gene to identify pathogenic variants causing autosomal recessive deafness type 91 (DFNB91). The test supports early clinical diagnosis, personalised hearing management, and informed reproductive planning for UAE families.
| Feature | Our Test | Usual Alternative |
|---|---|---|
| Methodology | NGS (full gene sequencing + CNV analysis) | Single‑gene Sanger or limited panel |
| Diagnostic Precision | 99.9% sensitivity; >100x mean coverage | ~95% for targeted regions |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Pre‑test Genetic Counselling | Mandatory, included | Often optional |
Physician Insight & Safety Protocols
From Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403): “The SERPINB6 test reveals whether a hidden genetic variant explains a patient’s hearing loss. It empowers families to pursue early cochlear intervention and make informed reproductive choices. Always correlate molecular findings with clinical audiometry—a gene change alone does not replace a thorough ear, nose and throat evaluation.”
Medication Advisory
Do not discontinue or modify any prescribed medication, including ototoxic drugs or steroids, without explicit consultation with your treating physician. This test does not replace therapeutic management.
Patient Safety – Exclusion Criteria & Red Flags
- Inability to provide informed consent without a legally authorised representative.
- Acute febrile illness or untreated infection that may compromise specimen integrity.
- Known haematological conditions preventing safe venipuncture – consider buccal swab or FTA card alternative.
- ER Red Flags: Sudden, rapidly progressive unilateral hearing loss with vertigo requires urgent ENT assessment. Signs of meningitis, head trauma, or acute otitis media must be addressed immediately.
Patient FAQ & Clinical Guidance
1. What is the SERPINB6 gene test and why is it important for hearing loss?
This test sequences the SERPINB6 gene to identify mutations causing autosomal recessive deafness type 91, enabling aetiological confirmation of congenital hearing loss. It helps differentiate genetic deafness from acquired causes, guiding long‑term audiological care, cochlear implant candidacy, and family risk assessment.
2. How is the test performed, and what sample is needed?
A small blood sample (5 mL EDTA whole blood) or a painless dried blood spot on an FTA card is collected by a mobile phlebotomist in your home or clinic. Extracted DNA from a prior sample is also accepted. No fasting is required. The specimen is transported under cold‑chain to our ISO‑accredited laboratory, where NGS analysis is completed in 3 to 4 weeks.
3. What do the results mean for me and my family?
A positive result confirms the genetic cause of deafness, allowing precise reproductive risk counselling with 25% recurrence per pregnancy for autosomal recessive inheritance. It may identify carrier status in siblings and parents, prompting cascade screening. A negative or uncertain result does not exclude all genetic hearing loss; follow‑up with your ENT and geneticist is essential.
4. Is pre‑test genetic counselling required?
Yes, a mandatory genetic counselling session is required to document a detailed family pedigree and obtain written informed consent. Provide the patient’s full clinical history, prior audiograms, and any previous genetic reports. No dietary restrictions or medication adjustments are necessary for this test.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: This service strictly adheres to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent follow Federal Decree‑Law No. 4 of 2016 on Medical Liability. Laboratory operations hold ISO 9001:2015 certification and are licensed by DHA/MOHAP.
Clinical & Logistical Metadata
| Test Name | SERPINB6 Gene Deafness, Autosomal Recessive Type 91 Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | 5 mL EDTA whole blood, dried blood spot on FTA card, or 2 µg extracted DNA |
| Methodology Used | Next‑Generation Sequencing (NGS) with CNV analysis |
| ICD-10-CM Code | H90.3, Z82.2, Z14.8 |
| LOINC Code | 81225-8 |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians